Inhibition of metadherin sensitizes breast cancer cells to AZD6244

Cancer Biology and Therapy

Volumn 13, Issue 1, 2012, Pages 43-49

  Kong, Xiaoli ^a   Moran, Meena S ^b   Zhao, Yuhan ^a   Yang, Qifeng ^a  

^a SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AZD6244; Breast cancer; FOXO3a; MTDH; Nuclear translocation

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; SELUMETINIB; TRANSCRIPTION FACTOR FKHRL1; BENZIMIDAZOLE DERIVATIVE; CELL ADHESION MOLECULE; FORKHEAD TRANSCRIPTION FACTOR; FOXO3 PROTEIN, HUMAN; MTDH PROTEIN, HUMAN; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; DOWN REGULATION; DRUG SENSITIZATION; GENE SILENCING; GENE TRANSLOCATION; MULTIDRUG RESISTANCE; ONCOGENE; ONCOGENE METADHERIN; PROTEIN EXPRESSION; BIOSYNTHESIS; BREAST TUMOR; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; FEMALE; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOLOGY; TUMOR CELL LINE; UPREGULATION;

APOPTOSIS; BENZIMIDAZOLES; BREAST NEOPLASMS; CELL ADHESION MOLECULES; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE KNOCKDOWN TECHNIQUES; HUMANS; RNA, SMALL INTERFERING; TRANSFECTION; UP-REGULATION;

EID: 84863034803     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.13.1.18868     Document Type: Article

References (48)

1. Igene H. Global health inequalities and breast cancer: an impending public health problem for developing countries. Breast J 2008; 14:428-34; PMID:18821930; http://dx.doi.org/10.1111/j.1524-4741.2008.00618.x
2. Krcova Z, Ehrmann J, Krejci V, Eliopoulos A, Kolar Z. Tpl-2/Cot and COX-2 in breast cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2008; 152:21-5; PMID:18795070
3. Weigelt B, Peterse JL, van 't Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer 2005; 5:591-602; PMID:16056258; http://dx.doi.org/10. 1038/nrc1670
4. Frieboes HB, Edgerton ME, Fruehauf JP, Rose FR, Worrall LK, Gatenby RA, et al. Prediction of drug response in breast cancer using integrative experimental/ computational modeling. Cancer Res 2009; 69:4484- 92; PMID:19366802; http://dx.doi.org/10.1158/ 0008-5472.CAN-08-3740
5. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70; PMID:10647931; http://dx.doi. org/10.1016/S0092-8674(00)81683-9
6. Osborne C, Wilson P, Tripathy D. Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications. Oncologist 2004; 9:361-77; PMID:15266090; http://dx.doi.org/ 10.1634/theoncologist.9-4-361
7. Gasparini G. Therapy of breast cancer with molecular targeting agents. Ann Oncol 2005; 16:iv28-36; PMID: 15923426; http://dx.doi.org/10.1093/annonc/ mdi905
8. Schlotter CM, Vogt U, Allgayer H, Brandt B. Molecular targeted therapies for breast cancer treatment. Breast Cancer Res 2008; 10:211; PMID:18671839; http://dx.doi.org/10.1186/bcr2112
9. Krishna M, Narang H. The complexity of mitogenactivated protein kinases (MAPKs) made simple. Cell Mol Life Sci 2008; 65:3525-44; PMID:18668205; http://dx.doi.org/10.1007/s00018-008-8170-7
10. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001; 22:153-83; PMID: 11294822; http://dx.doi.org/10.1210/er.22.2.153
11. Pagès G, Milanini J, Richard DE, Berra E, Gothie E, Vinals F, et al. Signaling angiogenesis via p42/p44 MAP kinase cascade. Ann N Y Acad Sci 2000; 902: 187-200; PMID:10865838; http://dx.doi.org/10. 1111/j.1749-6632.2000. tb06313.x
12. Joslin EJ, Opresko LK, Wells A, Wiley HS, Lauffenburger DA. EGF-receptor-mediated mammary epithelial cell migration is driven by sustained ERK signaling from autocrine stimulation. J Cell Sci 2007; 120:3688-99; PMID:17895366; http://dx.doi.org/10. 1242/jcs.010488
13. Price DJ, Avraham S, Feuerstein J, Fu Y, Avraham HK. The invasive phenotype in HMT-3522 cells requires increased EGF receptor signaling through both PI 3- kinase and ERK 1,2 pathways. Cell Commun Adhes 2002; 9:87-102; PMID:12487410; http://dx.doi.org/ 10.1080/15419060214147
14. Nishioka C, Ikezoe T, Yang J, Yokoyama A. Inhibition of MEK/ERK signaling induces apoptosis of acute myelogenous leukemia cells via inhibition of eukaryotic initiation factor 4E-binding protein 1 and downregulation of Mcl-1. Apoptosis 2010; 15:795-804; PMID:20221697; http://dx.doi.org/10.1007/s10495- 010-0483-y
15. Meng J, Fang B, Liao Y, Chresta CM, Smith PD, Roth JA. Apoptosis induction by MEK inhibition in human lung cancer cells is mediated by Bim. PLoS ONE 2010; 5:e13026; PMID:20885957; http://dx.doi.org/10. 1371/journal.pone. 0013026
16. Friday BB, Yu C, Dy GK, Smith PD, Wang L, Thibodeau SN, et al. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins. Cancer Res 2008; 68:6145-53; PMID:18676837; http://dx.doi.org/10.1158/0008-5472.CAN-08-1430
17. Yoon J, Koo KH, Choi KY. MEK1/2 Inhibitors AS703026 and AZD6244 may be potential therapies for kras mutated colorectal cancer that is resistant to egfr monoclonal antibody therapy. Cancer Res 2011; 71:445-53; PMID:21118963; http://dx.doi.org/10. 1158/0008-5472.CAN-10-3058
18. Yoon YK, Kim HP, Han SW, Oh do Y, Im SA, Bang YJ, et al. KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach. Mol Carcinog 2010; 49:353-62; PMID: 20358631; http://dx.doi.org/10.1002/mc.20607
19. Garon EB, Finn RS, Hosmer W, Dering J, Ginther C, Adhami S, et al. Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines. Mol Cancer Ther 2010; 9:1985-94; PMID:20587667; http://dx.doi.org/10.1158/1535-7163.MCT-10-0037
20. Ball DW, Jin N, Rosen DM, Dackiw A, Sidransky D, Xing M, et al. Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244. J Clin Endocrinol Metab 2007; 92:4712-8; PMID:17878251; http://dx.doi.org/10.1210/jc.2007-1184
21. Yang JY, Chang CJ, Xia W, Wang Y, Wong KK, Engelman JA, et al. Activation of FOXO3a is sufficient to reverse mitogen-activated protein/extracellular signalregulated kinase kinase inhibitor chemoresistance in human cancer. Cancer Res 2010; 70:4709-18; PMID: 20484037; http://dx.doi.org/10.1158/0008-5472.CAN- 09-4524
22. Davies BR, Logie A, McKay JS, Martin P, Steele S, Jenkins R, et al. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther 2007; 6:2209-19; PMID: 17699718; http://dx.doi.org/10.1158/1535-7163.MCT- 07-0231
23. Adjei AA, Cohen RB, Franklin W, Morris C, Wilson D, Molina JR, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 2008; 26:2139-46; PMID: 18390968; http://dx.doi.org/10.1200/JCO.2007.14. 4956
24. Hainsworth JD, Cebotaru CL, Kanarev V, Ciuleanu TE, Damyanov D, Stella P, et al. A phase II, openlabel, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens. J Thorac Oncol 2010; 5:1630-6; PMID:20802351; http://dx. doi.org/10.1097/JTO. 0b013e3181e8b3a3
25. Bennouna J, Lang I, Valladares-Ayerbes M, Boer K, Adenis A, Escudero P, et al. A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens. Invest New Drugs 2011; 29:1021-8; PMID:20127139; http://dx.doi.org/10.1007/s10637- 010-9392-8
26. Kolb EA, Gorlick R, Houghton PJ, Morton CL, Neale G, Keir ST, et al. Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 2010; 55:668-77; PMID:20806365; http://dx.doi.org/10.1002/pbc.22576
27. Gopal YN, Deng W, Woodman SE, Komurov K, Ram P, Smith PD, et al. Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res 2010; 70: 8736-47; PMID:20959481; http://dx.doi.org/10. 1158/0008-5472.CAN-10- 0902
28. Su ZZ, Kang DC, Chen Y, Pekarskaya O, Chao W, Volsky DJ, et al. Identification and cloning of human astrocyte genes displaying elevated expression after infection with HIV-1 or exposure to HIV-1 envelope glycoprotein by rapid subtraction hybridization, RaSH. Oncogene 2002; 21:3592-602; PMID:12032861; http://dx.doi.org/10.1038/sj.onc.1205445
29. Li C, Liu J, Lu R, Yu G, Wang X, Zhao Y, et al. AEG -1 Overexpression: A novel indicator for peritoneal dissemination and lymph node metastasis in epithelial ovarian cancers. Int J Gynecol Cancer 2011; 21:602-8; PMID:21543927; http://dx.doi.org/10.1097/IGC. 0b013e3182145561
30. Yu C, Chen K, Zheng H, Guo X, Jia W, Li M, et al. Overexpression of astrocyte elevated gene-1 (AEG-1) is associated with esophageal squamous cell carcinoma (ESCC) progression and pathogenesis. Carcinogenesis 2009; 30:894-901; PMID:19304953; http://dx.doi. org/10.1093/carcin/bgp064
31. Yoo BK, Emdad L, Su ZZ, Villanueva A, Chiang DY, Mukhopadhyay ND, et al. Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. J Clin Invest 2009; 119:465-77; PMID: 19221438; http://dx.doi.org/10.1172/JCI36460
32. Hu G, Chong RA, Yang Q, Wei Y, Blanco MA, Li F, et al. MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. Cancer Cell 2009; 15:9-20; PMID: 19111877; http://dx.doi.org/10. 1016/j.ccr.2008.11.013
33. Emdad L, Lee SG, Su ZZ, Jeon HY, Boukerche H, Sarkar D, et al. Astrocyte elevated gene-1 (AEG-1) functions as an oncogene and regulates angiogenesis. Proc Natl Acad Sci USA 2009; 106:21300-5; PMID: 19940250; http://dx.doi.org/10. 1073/pnas.0910936106
34. Song L, Li W, Zhang H, Liao W, Dai T, Yu C, et al. Over-expression of AEG-1 significantly associates with tumour aggressiveness and poor prognosis in human non-small cell lung cancer. J Pathol 2009; 219:317-26; PMID:19644957; http://dx.doi.org/10.1002/path.2595
35. Li C, Li R, Song H, Wang D, Feng T, Yu X, et al. Significance of AEG-1 expression in correlation with VEGF, microvessel density and clinicopathological characteristics in triple-negative breast cancer. J Surg Oncol 2011; 103:184-92; PMID:21259255; http://dx. doi.org/10.1002/jso.21788
36. Kikuno N, Shiina H, Urakami S, Kawamoto K, Hirata H, Tanaka Y, et al. Knockdown of astrocyte-elevated gene-1 inhibits prostate cancer progression through upregulation of FOXO3a activity. Oncogene 2007; 26:7647-55; PMID:17563745; http://dx.doi.org/10. 1038/sj.onc.1210572
37. Li J, Yang L, Song L, Xiong H, Wang L, Yan X, et al. Astrocyte elevated gene-1 is a proliferation promoter in breast cancer via suppressing transcriptional factor FOXO1. Oncogene 2009; 28:3188-96; PMID: 19633686; http://dx.doi.org/10.1038/onc.2009.171
38. Su P, Zhang Q, Yang Q. Immunohistochemical analysis of Metadherin in proliferative and cancerous breast tissue. Diagn Pathol 2010; 5:38; PMID:20565850; http://dx.doi.org/10.1186/1746-1596-5-38
39. Li X, Kong X, Huo Q, Guo H, Yan S, Yuan C, et al. Metadherin enhances the invasiveness of breast cancer cells by inducing epithelial to mesenchymal transition. Cancer Sci 2011; 102:1151-7; PMID:21371176; http://dx.doi.org/10. 1111/j.1349-7006.2011.01919.x
40. Khuda II, Koide N, Noman AS, Dagvadorj J, Tumurkhuu G, Naiki Y, et al. Astrocyte elevated gene-1 (AEG-1) is induced by lipopolysaccharide as toll-like receptor 4 (TLR4) ligand and regulates TLR4 signalling. Immunology 2009; 128:e700-6; PMID: 19740331; http://dx.doi.org/10.1111/j.1365-2567. 2009.03063.x
41. Dry JR, Pavey S, Pratilas CA, Harbron C, Runswick S, Hodgson D, et al. Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer Res 2010; 70:2264-73; PMID: 20215513; http://dx.doi.org/10.1158/0008-5472.CAN- 09-1577
42. Meng J, Peng H, Dai B, Guo W, Wang L, Ji L, et al. High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886). Cancer Biol Ther 2009; 8:2073-80; PMID:19783898; http:// dx.doi.org/10.4161/cbt. 8.21.9844
43. Roy SK, Srivastava RK, Shankar S. Inhibition of PI3K/ AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer. J Mol Signal 2010; 5:10; PMID:20642839; http://dx.doi.org/10.1186/ 1750-2187-5-10
44. Yang JY, Zong CS, Xia W, Yamaguchi H, Ding Q, Xie X, et al. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol 2008; 10:138-48; PMID:18204439; http://dx.doi. org/10.1038/ncb1676
45. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999; 96:857-68; PMID:10102273; http://dx.doi.org/ 10.1016/S0092-8674(00) 80595-4
46. Tentler JJ, Nallapareddy S, Tan AC, Spreafico A, Pitts TM, Morelli MP, et al. Identification of Predictive Markers of Response to the MEK1/2 Inhibitor Selumetinib (AZD6244) in K-ras-Mutated Colorectal Cancer. Mol Cancer Ther 2010; 9:3351-62; PMID: 20923857; http://dx.doi.org/10.1158/1535-7163.MCT- 10-0376
47. Liu H, Song X, Liu C, Xie L, Wei L, Sun R. Knockdown of astrocyte elevated gene-1 inhibits proliferation and enhancing chemo-sensitivity to cisplatin or doxorubicin in neuroblastoma cells. J Exp Clin Cancer Res 2009; 28:19; PMID:19216799; http://dx.doi.org/10. 1186/1756-9966-28-19
48. Hu MC, Lee DF, Xia W, Golfman LS, Ou-Yang F, Yang JY, et al. IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 2004; 117:225-37; PMID:15084260; http://dx.doi.org/10. 1016/S0092-8674(04)00302-2